Hormonal Therapy News and Research RSS Feed - Hormonal Therapy News and Research

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Drug combination therapy delays progression of advanced breast cancer without side effects, study shows

Drug combination therapy delays progression of advanced breast cancer without side effects, study shows

Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone. [More]
Study shows menopausal hormone therapy can improve bone mass and structure

Study shows menopausal hormone therapy can improve bone mass and structure

Women who undergo hormone therapy for menopausal symptoms such as hot flashes can not only increase bone mass, but also can improve bone structure, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Identifying gene defects may help develop individualised treatments for prostate cancer patients

Identifying gene defects may help develop individualised treatments for prostate cancer patients

The current method of treating prostate cancer involves identifying gene defects, which could help with the diagnosis of cancer and the development of individualised cancer treatments for patients. [More]
Painful sex in women after cancer needs to be addressed, UC Davis researcher suggests

Painful sex in women after cancer needs to be addressed, UC Davis researcher suggests

Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests. [More]
Study examines benefits of hormonal therapy for prostate cancer patients with prior history of heart attack

Study examines benefits of hormonal therapy for prostate cancer patients with prior history of heart attack

In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. [More]
ATS releases new clinical practice guidelines for diagnosis, management of LAM

ATS releases new clinical practice guidelines for diagnosis, management of LAM

The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age. [More]
PSA failure linked to increased risk of death among healthy men

PSA failure linked to increased risk of death among healthy men

A new study by investigators at Brigham and Women's Hospital has found that a rise in prostate-specific antigen (PSA) levels in healthy men who have previously been treated for prostate cancer is significantly associated with a 1.6-fold increased risk of death. [More]
New research discovers how opposite-sex hormonal therapy influences the brain

New research discovers how opposite-sex hormonal therapy influences the brain

Women and men often show marked differences as regards mental illnesses. In order to learn more about this phenomenon, a project supported by the Austrian Science Fund FWF explored how opposite-sex hormonal therapy applied to transgender individuals influences the brain. [More]
Researchers to develop new test to predict therapy for women with ER+ breast cancer

Researchers to develop new test to predict therapy for women with ER+ breast cancer

Researchers from Case Western Reserve University are teaming with industry and other academics to develop a quick and inexpensive test to predict which women with ER+ breast cancer need chemotherapy and which need only the more tolerable hormonal therapy. [More]
Intrinsic subtyping of breast cancer can aid prognosis, treatment of tumor patients

Intrinsic subtyping of breast cancer can aid prognosis, treatment of tumor patients

Published in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s Translational Genomics Group, Team Leader of translational genomics and targeted therapeutics in solid tumors at the August Pi I Sunyer Biomedical Research Institute, and Head of Medical Oncology at the Hospital Clínic in Barcelona, Aleix Prat has led a study showing the intrinsic subtyping of breast cancer by means of a genomic test as the most important prognostic factor in advanced or metastatic hormone-sensitive breast cancer. [More]
New research reveals advances that could change gynecologic cancer standard-of-care treatments

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology. [More]
Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed. [More]
Researchers spot molecular key that breast cancer cells use to invade bone marrow

Researchers spot molecular key that breast cancer cells use to invade bone marrow

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise eradicate them. [More]
Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis. [More]
Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation. [More]
Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
Active surveillance may be a viable treatment for select DCIS patients

Active surveillance may be a viable treatment for select DCIS patients

Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ, or DCIS, according to a mathematical model developed by researchers at Duke University. [More]
Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease. [More]
Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage. [More]
Advertisement
Advertisement